Company intelligence / Profile preview

TRX Orthopedics

Leeds, England, United Kingdompmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Employees: ~100
Development stage: Other

Overview

OrthoPure™ XT has completed clinical trials in the EU with data submitted for CE approval. DermaPure is commercially available with demonstrated positive outcomes in wound healing. The company’s decellularized scaffolds are designed to reduce immune response while supporting natural regeneration.

Therapeutic areas: DermatologyRheumatologyOther
Modalities: BiologicDevice (biological implants and tissue-based products)Scaffold-based regenerative therapy
Industry: Implantable Medical Devices

Partnerships

Premier Inc. (US healthcare improvement network)various hospital systems

Beyond the preview

Go deeper on TRX Orthopedics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRX Orthopedics.

Explore the full profile